Soligenix (NASDAQ:SNGX) Announces Earnings Results

Soligenix (NASDAQ:SNGX) announced its earnings results on Friday. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05, Zacks reports.

Soligenix Stock Up 0.5%

Shares of NASDAQ SNGX opened at $0.34 on Friday. The business’s 50 day moving average is $0.36 and its two-hundred day moving average is $0.67. Soligenix has a 52-week low of $0.28 and a 52-week high of $1.70. The firm has a market cap of $4.96 million, a price-to-earnings ratio of -0.34 and a beta of 2.04.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a research report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Soligenix presently has an average rating of “Sell”.

Soligenix Company Profile

Soligenix, Inc is a U.S.-based biopharmaceutical company focused on developing treatments for rare diseases and serious medical conditions with limited therapeutic options. The company’s programs are primarily aimed at immunology, inflammation, infectious diseases and oncology, with an emphasis on advancing candidates through clinical development and regulatory approval.

Soligenix’s pipeline has included SGX301, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma; SGX942, an innate defense regulator investigated for inflammatory conditions such as oral mucositis; and SGX945, a related candidate studied for Behçet’s disease.